# VolitionRx Limited (VNRX)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $153M  
**Price:** $1.43 (+2.88%)

> VolitionRx Limited is a multinational epigenetics company specializing in the development and commercialization of blood-based diagnostic tests. Its primary focus is on applying its proprietary Nucleosomics platform to detect and measure nucleosomes and related biomarkers in blood and other bodily fluids, supporting the diagnosis and monitoring of life-altering diseases, including certain cancers and conditions associated with NETosis such as sepsis. The company aims to provide simple, easy-to-use, and cost-effective assays that can be integrated into routine clinical workflows, helping healthcare providers obtain actionable information on disease presence and progression. VolitionRx today operates through a network of subsidiaries, with research and development centered in Belgium and additional operations in the United States, United Kingdom, and Singapore. Headquartered in Henderson, Nevada, and founded in 2010, VolitionRx Limited serves the global human and veterinary diagnostics markets, offering tools that support earlier detection and ongoing treatment monitoring across multiple therapeutic areas.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2M | — | -$22M | -$23M | — |
| 2024 | $1M | — | -$27M | -$27M | — |
| 2023 | $775,302 | — | -$36M | -$36M | — |
| 2022 | $306,392 | — | -$32M | -$31M | — |
| 2021 | $90,035 | — | -$28M | -$27M | — |
| 2020 | $13,433 | — | -$21M | -$20M | — |
| 2019 | $17,096 | — | -$16M | -$16M | — |
| 2014 | $14,785 | — | -$6M | -$8M | — |
| 2012 | $54,968 | — | -$4M | -$4M | — |
| 2011 | — | — | -$3M | -$3M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $7M | $42M | -$34M | $1M | $7M |
| 2024 | $9M | $36M | -$25M | $3M | $5M |
| 2023 | $28M | $37M | -$8M | $21M | $5M |
| 2022 | $18M | $21M | -$3M | $11M | $4M |
| 2021 | $27M | $10M | $18M | $21M | $3M |
| 2020 | $26M | $10M | $16M | $19M | $3M |
| 2019 | $21M | $7M | $14M | $17M | $3M |
| 2014 | $3M | $3M | $368,179 | $2M | — |
| 2012 | $2M | $1M | $833,795 | $376,421 | — |
| 2011 | $2M | $1M | $1M | $347,892 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$20M | $89,558 | -$20M |
| 2024 | -$26M | $277,499 | -$26M |
| 2023 | -$18M | $1M | -$19M |
| 2022 | -$15M | $2M | -$17M |
| 2021 | -$21M | $973,559 | -$22M |
| 2020 | -$16M | $2M | -$18M |
| 2019 | -$13M | $511,266 | -$13M |
| 2018 | -$15M | -$301,805 | -$15M |
| 2017 | -$12M | $1M | -$14M |
| 2016 | -$9M | $415,091 | -$9M |
| 2015 | -$9M | $77,195 | -$9M |
| 2014 | -$4M | $302,989 | -$4M |
| 2013 | -$3M | $714 | -$3M |
| 2012 | -$2M | $90,685 | -$2M |
| 2011 | -$2M | $34,865 | -$2M |

Source: [CompaniesByCap](https://companiesbycap.com/company/VNRX)